I’ve been blogging about stem cells now for about 8 years and the recent level of hype about and fluffy media coverage of Celularity, the biotech spun out of Celgene, ranks right up here with the most extreme past cases I’ve seen. What is Celularity and who is its leadership? It’s a new biotech focused […]
Just one word placentas: Can Celularity live up to hype? Read More »
My first job in science was as a lab technician at UCSD School of Medicine and a big part of that job was growing cells called HUVECs or human umbilical vein endothelial cells. We isolated and grew the HUVECs from umbilical cords that we retrieved from the maternity ward of the UCSD hospital, which first
Why we shouldn’t view the human embryo as a gizmo even in the CRISPR era Read More »
Is monkey cloning a good idea? We’re about to find out. A new Cell paper today reports the first cloning of monkeys via somatic cell nuclear transfer (SCNT), raising many questions. The paper from a team led by Qiang Sun is entitled, “Cloning of Macaque Monkeys by Somatic Cell Nuclear Transfer.” The highlight bullet points
Is monkey cloning a breakthrough or a bad idea? Read More »
A team of researchers at RIKEN and Kobe City Medical Center reported at a press conference today a serious adverse event in a clinical trial participant receiving an induced pluripotent stem cell (IPS cell)-based therapy for vision loss. According to Japan Times and Yahoo! Japan (in Japanese), the patient in question in the IPS cell
Adverse event in IPS cell (ips細胞) trial for vision loss in Japan: initial perspectives Read More »
The news that CRISPR-Cas9 gene editing in its current form may not work in a substantial fraction of people due to many of us having immunity to Cas9 came as a shock to many, but if you think about it, maybe it’s not so surprising. I don’t see it as the end of the world. A (preprint) from
Keep calm & CRISPR on: perspectives on report of human Cas9 immunity Read More »
Australian stem cell biotech Mesoblast announced that it has received regenerative medicine advanced therapy (RMAT) designation from the U.S. FDA. This is very good news for the company and an encouraging development for the field. Interestingly, last month the FDA clarified that there is expanded RMAT designation that can include gene therapies too. At the Meeting
Mesoblast gets FDA RMAT; List of 10 total designations so far Read More »
By Samantha Yammine When our TV stops working, it’s usually because one of the wires has come unplugged. We begrudgingly huff and puff over to the back of the TV, track down the loose culprit, plug it back in, and boom: back to Netflix. If you multiply all those wires in the back of your
By Jeanne Loring There are ten million people in the world who have Parkinson’s disease. 125,000 of these are living in California. People with the disease often have to step away from their jobs because the main symptoms – tremor or freezing up of muscles – make it difficult to get through a whole day
On the threshold of cell therapy for Parkinson’s disease Read More »
Human germline CRISPR raises major bioethical considerations, but what about technical issues? Setting aside the many ethical issue about the general idea of human modification itself, could this really work? Yes in theory it could, but there are some very tough technological challenges that could and likely would cause failures or unacceptable outcomes at many steps
7 tech hurdles to human germline CRISPR Read More »
Some notable newly published Phase II data from the Duke cord blood for cerebral palsy trial unfortunately doesn’t give much reason for optimism that this approach is going to have a substantial positive effect for these kids. The double-blinded, placebo-controlled study did not find a meaningful benefit overall from infusions of autologous cord blood (ACB) for
Cord blood for cerebral palsy: mostly discouraging new trial data Read More »